Hemant Surgical Industries shareholding pattern

HSIL

292.55

4.40 (-1.48%)
Last updated on 20 Feb, 2026 | 15:55 IST
alert_iconwatchlist_icon
BUYSELL
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Hemant Surgical Industries Shareholding Pattern

  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

58.9%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

0.15%

Domestic Institutional Investors

10.81%

Retail

30.14%

Others

0%

Total Promoters
MAR '25
73.56%
JUN '25
58.9%
SEP '25
58.9%

Summary

For Year 2025-26, Hemant Surgical Industries reports the following shareholding: Total Promoters at 58.9%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0.15%, Domestic Institutional Investors at 10.81%, and Retail at 30.14%. This breakdown provides a quick snapshot of ownership distribution for Hemant Surgical Industries in 2025-26.

Hemant Surgical Industries FAQs

As of 02-2026, the promoter shareholding in Hemant Surgical Industries stands at 58.9% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Hemant Surgical Industries is 0.15% and 10.81% respectively.

The retail shareholding of the Hemant Surgical Industries is 30.14%.

Changes in shareholding patterns of Hemant Surgical Industries can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Hemant Surgical Industries are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost